Research programme: mucosal vaccines - Mucosis

Drug Profile

Research programme: mucosal vaccines - Mucosis

Alternative Names: Hepatitis B vaccine - Mucosis; Malaria vaccine - Mucosis; Plague vaccine - Mucosis; PneuGEM; Shigella and other enteric bacterial pathogens vaccines - Mucosis; Yersinia pestis vaccine - Mucosis

Latest Information Update: 24 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Mucosis; Virtuvax
  • Developer Mucosis; University of Copenhagen
  • Class Antibodies; Bacterial vaccines; Glycoproteins; Hepatitis B vaccines; Membrane fusion proteins; Parasitic vaccines; Pneumococcal vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis B; Malaria; Otitis media; Pneumococcal infections; Pneumonia; Respiratory syncytial virus infections; Shigella infections; Yersinia infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Respiratory-syncytial-virus-infections(Prevention) in Netherlands (Intranasal, Drops)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Malaria(Prevention) in Netherlands (Intranasal)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pneumococcal-infections(Prevention) in Netherlands (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top